A Botanical Mixture of Boswellia serrata, Commiphora myrrha, Propolis and Scutellaria baicalensis Reduces Expression of Inflammatory Chemokines in Canine Keratinocytes In Vitro.
- 2026-05-01
- Veterinary medicine and science 12(3)
- PubMed: 42057627
- DOI: 10.1002/vms3.70963
Study Design
- Methods
- In vitro experiments: HPLC analysis; treatment of RAW 264.7 and CPEK cells with YSK-AB; measurement of NO, cell viability, CCL2, CCL5, CCL17.
- Funding
- Unclear
- Animal Study
Botanical ingredients can function as adjunctive therapies for managing inflammatory skin diseases. This study aimed to investigate the anti-inflammatory effects of a mixture of Boswellia serrata, Commiphora myrrha, propolis and Scutellaria baicalensis (YSK-AB) on canine keratinocytes in vitro. High-performance liquid chromatography (HPLC) was used to identify major components of YSK-AB. In addition, to evaluate nitric oxide (NO) production, RAW 264.7 cells were treated with YSK-AB (25, 50, 100 and 200 µg/mL) for 24 h, subsequently stimulated with lipopolysaccharide (1 µg/mL). To analyse the cytotoxic effects of YSK-AB, canine progenitor epidermal keratinocytes (CPEKs) were incubated with YSK-AB for 48 h. To investigate the effects of YSK-AB on cytokine expression, CPEKs were incubated with YSK-AB for 24 h and then stimulated with a mixture of interferon-γ and tumour necrosis factor-α (30 ng/mL each) for 24 h. The enzyme-linked immunosorbent assay (ELISA) was performed to measure chemokine (C-C motif) ligand 2 (CCL2) and CCL5. Real-time polymerase chain reaction (PCR) was used to quantify CCL17 mRNA expression. HPLC analysis identified four components in YSK‑AB, including 6‑hydroxy‑2,6‑dimethylhepta‑2,4‑dienal, baicalin, galangin and AKBA. CPEKs treated with 100, 150, 200 and 250 µg/mL of YSK‑AB exhibited significantly higher viability than that of the control group. In addition, YSK‑AB treatment (50, 100 and 200 µg/mL) significantly reduced NO production in RAW 264.7 cells. Furthermore, CCL17 mRNA expression and CCL2 and CCL5 protein levels were significantly reduced in YSK‑AB‑treated CPEKs compared with the control. YSK-AB downregulates the expression of chemokines produced by canine keratinocytes and could be a potential novel natural product-derived therapeutic agent for alleviating inflammatory skin diseases in dogs.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|